Shariff S. Bayoumy – Managing Partner

Cell Biology – B.S. (U. Rochester); M.S. (Hunter CUNY)

Led Janssen North America gene-to-protein team in support of soluble and membrane proteins for small molecule discovery SBDD, FBDD, HTS campaigns

Unique expertise in GPCR expression, stabilization, and purification

New technology scouting and implementation for protein expression, cell line development, and functional genomics

17 years in biotech and pharma; 15 peer reviewed papers; co-inventor on 2 patents

Lawrence C. Kuo – Managing Partner

Biophysics – Ph.D. (U. Chicago); Jane Coffin Childs Fellow (Harvard)

Associate Professor (Boston University)

Pew Scholar (Pew Charitable Trust); RCDA Fellow (NIH)

Head, Structural Biology (J&J PRD, PA)

Head, Enzymology and Structural Biology (Merck Research Lab, PA)

Core member of project teams that brought Crixivan™ and Stocrin™ to market

23 years in pharma; co-inventor on 18 patents; 115 peer reviewed papers; editor of 3 books

Brett A. Tounge – Managing Partner

Physical Chemistry – Ph.D. (Yale); American Cancer Society Post-Doctoral Fellow (Brandeis/MIT jointly)

Extensive expertise in designing drug-like small molecules from hit discovery through NME declaration

Established and ran protein NMR group focused on solution structure determination and dynamics (Janssen Pharmaceuticals)

Expertise in multiple early- and late-stage drug discovery areas including central nervous systems disorders, pain, metabolic diseases, oncology, infectious diseases, and inflammation

14 years in pharma; co-inventor on 12 patents; 33 peer reviewed papers; 2 book chapters

James Barrett, PhD – Neuropsychopharmacology/Substance Abuse Advisor

Professor of Neurology at Drexel School of Medicine

Founding Director, Drug Discovery and Clinical Translational Research Institute at Drexel University

Former VP, SVP, CSO in Pain and CNS Disorders at Lederle, Wyeth, Memory Pharma, Adolor

Published over 300 scientific articles

Scott A. Reines, MD, PhD – Chief Medical Officer

Former SVP of CNS, Pain, Translation Medicine at J&J

Former VP of Clinical Research at Merck

Oversaw development/approval of Invega®, Nucynta®, Reminyl-ER®, Risperidal Consta®, Risperidal®, and Topamax®

Led development of Emend®, Maxalt®, Sinemet-CR® Trusopt®, Cosopt®, and Timoptic-XE®

Greg Harriman, MD – Medical, Scientific, and Venture Advisor

Venture Partner of BioAdvance

Over 25 years of experience in academic medicine and biopharmaceutical industry

Led clinical R&D groups responsible for development of both drugs and biologics

Robert Besthof, BA, MIM – Partner, Commercial and Business Development

5 Years banking and consulting

23 years pharmaceutical experience at Lilly, Wyeth, and Pfizer

10+ years Global Strategic Marketing and shaping emerging pipelines

Former Vice President Neuroscience & Pain at Pfizer

Master of International Management, Glendale, Arizona, USA
American Graduate School of International Management (Thunderbird)

Bachelor of Arts in Economics: Case Western Reserve University, Cleveland, Ohio, USA